Gapping up
In reaction to strong earnings/guidance: SMCI +17.2%, SKX +13.9%, SGOC +13.5% (thinly traded), XOOM +12.9%, FDML +9%, (light volume), ILMN +8.8%, NEO +8.7%, (light volume, also extends/amends Strategic Laboratory Services Agreement with Florida Cancer Specialists), SWKS +8.4%, ETH +8%, (light volume), SANM +7.9%, MANH +5.7%, SVU +5.8% (ticking higher), DPS +4.9%, GILD +3.9%, MAN +3.5%, (light volume), HERO +3.4%, (light volume), JAKK +3.1%, BA +2.5%, DAL +2.3%, YUM +2%, NSC +1.6%, PKG +1.5% (light volume), CVA +1.4% (light volume), DOW +1.2%, WRB +1.1% (light volume), HTS +1%.
Select metals/mining stocks trading higher: GOLD +0.7%, GDX +0.5%, NEM +0.4% (ongoing ABX merger speculation), GLD +0.2%.
European pharma/drug names trading higher: AZN +1.7% , NVS +1.6%, GSK +0.7% (upgraded to Buy from Hold at Argus)
Other news: ATRM +21.5% (Aetrium announces value-enhancing transaction for its test handler business), SPPI +11% (Spectrum Pharma's Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint; co expects to file an NDA in Q3 and plans to launch this drug with its existing hematology/oncology sales force next year pending approval), BIOD +4.4% (announces collaboration agreement with HEC Pharm for development of Ultra-Rapid-Acting Insulin Aspart Formulation), UNIS +3.4% (UNS Energy responds to Blog article), UQM +2.5% (UQM Technologies and Kinetics Drive Solutions Collaborate on Electric Drive Systems for All-Electric Commercial Vehicles), YELP +2.5% (positive MadMoney mention), ALU +2% (still checking), YNDX+1.9% (still checking), TQNT +0.9% (following SWKS results), CHFN +0.8% ( completed its initial stock buyback program and initiated a new repurchase program under which co may repurchase up to 2,250,000 shares of its common stock), AGN +0.8% (Allergan adopts one-year Stockholder Rights Plan; upgraded to Overweight from Neutral at JPMorgan), HAL +0.5% (positive MadMoney mention), SUNE +0.4% (Closes CAD115 Million In Financing To Build 33 MW Of Utility Solar Projects In Ontario, Canada).
Analyst comments: ATHN +4.3% (upgraded to Overweight from Equal Weight at Morgan Stanley), SPWR +2.8% (upgraded to Buy from Underperform at BofA/Merrill), VSI +1.3% (Vitamin Shoppe upgraded to Buy from Neutral at Sterne Agee), MDSO +0.7% ( upgraded to Buy from Neutral at B. Riley), ETFC +0.5% (upgraded to Outperform from Market Perform at Wells Fargo), SSYS +0.4% (3D printing mentioned positively in Citigroup Q1 preview; continues to view SSYS as top pick)
Select metals/mining stocks trading higher: GOLD +0.7%, GDX +0.5%, NEM +0.4% (ongoing ABX merger speculation), GLD +0.2%.
European pharma/drug names trading higher: AZN +1.7% , NVS +1.6%, GSK +0.7% (upgraded to Buy from Hold at Argus)
Other news: ATRM +21.5% (Aetrium announces value-enhancing transaction for its test handler business), SPPI +11% (Spectrum Pharma's Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint; co expects to file an NDA in Q3 and plans to launch this drug with its existing hematology/oncology sales force next year pending approval), BIOD +4.4% (announces collaboration agreement with HEC Pharm for development of Ultra-Rapid-Acting Insulin Aspart Formulation), UNIS +3.4% (UNS Energy responds to Blog article), UQM +2.5% (UQM Technologies and Kinetics Drive Solutions Collaborate on Electric Drive Systems for All-Electric Commercial Vehicles), YELP +2.5% (positive MadMoney mention), ALU +2% (still checking), YNDX+1.9% (still checking), TQNT +0.9% (following SWKS results), CHFN +0.8% ( completed its initial stock buyback program and initiated a new repurchase program under which co may repurchase up to 2,250,000 shares of its common stock), AGN +0.8% (Allergan adopts one-year Stockholder Rights Plan; upgraded to Overweight from Neutral at JPMorgan), HAL +0.5% (positive MadMoney mention), SUNE +0.4% (Closes CAD115 Million In Financing To Build 33 MW Of Utility Solar Projects In Ontario, Canada).
Analyst comments: ATHN +4.3% (upgraded to Overweight from Equal Weight at Morgan Stanley), SPWR +2.8% (upgraded to Buy from Underperform at BofA/Merrill), VSI +1.3% (Vitamin Shoppe upgraded to Buy from Neutral at Sterne Agee), MDSO +0.7% ( upgraded to Buy from Neutral at B. Riley), ETFC +0.5% (upgraded to Outperform from Market Perform at Wells Fargo), SSYS +0.4% (3D printing mentioned positively in Citigroup Q1 preview; continues to view SSYS as top pick)